Synthetic cannabinoid quinones: Preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity

European Journal of Medicinal Chemistry

Volumn 70, Issue , 2013, Pages 111-119

  Morales, Paula ^a   Vara, Diana ^b   Goméz Cañas, María ^c   Zúñiga, María C ^d   Olea Azar, Claudio ^d   Goya, Pilar ^a   Fernández Ruiz, Javier ^c   Díaz Laviada, Inés ^b   Jagerovic, Nadine ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d UNIVERSITY OF CHILE   (Chile)

Author keywords

Antiproliferative; Antitumor; Cannabinoid; Chromenopyrazoledione; Electrochemistry; Prostate cancer; Quinone

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 7 (1',1' DIMETHYLHEPTYL) 1,4 DIHYDRO 4,4 DIMETHYLCHROMENO [4,3 C]PYRAZOL 6,9 DIONE; 7 (1',1' DIMETHYLHEPTYL) 2 ETHYL 2,4 DIHYDRO 4,4 DIMETHYLCHROMENO [4,3 C]PYRAZOL 6,9 DIONE; 7 (1',1' DIMETHYLHEPTYL) 2,4 DIHYDRO 2,4,4 TRIMETHYLCHROMENO [4,3 C]PYRAZOL 6,9 DIONE; ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL DEATH; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; DRUG SYNTHESIS; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PROSTATE CANCER; RECEPTOR AFFINITY; TUMOR VOLUME;

ANTIPROLIFERATIVE; ANTITUMOR; CANNABINOID; CHROMENOPYRAZOLEDIONE; EBNA; ELECTROCHEMISTRY; EPSTEIN-BARR VIRUS NUCLEAR ANTIGEN; FITC; FLUORESCEIN ISOTHIOCYANATE; HEPG2; HEPTOBLASTOMA; HT-29; HUMAN COLON ADENOCARCINOMA; LNCAP; LYMPH NODE CARCINOMA PROSTATE; PBS; PC-3; PHOSPHATE BUFFERED SALINE; PI; PROPIDIUM IODIDE; PROSTATE CANCER; QUINONE; REACTIVE OXYGEN SPECIES; ROS; S.D.; S.E.; STANDARD DEVIATION; STANDARD ERROR; TBAP; TETRABUTYLAMMONIUM PERCHLORATE;

ANIMALS; ANTINEOPLASTIC AGENTS; CANNABINOIDS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LIVER NEOPLASMS; MALE; MICE; MOLECULAR STRUCTURE; PROSTATIC NEOPLASMS; QUINONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84885500963     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.09.043     Document Type: Article

References (33)

1. L.G. Gomella, X.L.S. Liu, E.J. Trabulsi, W.K. Kelly, R. Myers, T. Showalter, A. Dicker, and R. Wender Screening for prostate cancer: the current evidence and guidelines controversy Can. J. Urol. 18 2011 5875 5883
2. W.H. Fu, E. Madan, M. Yee, and H.T. Zhang Progress of molecular targeted therapies for prostate cancers BBA Rev. Cancer 1825 2012 140 152
3. N.M. O'Boyle, and M.J. Meegan Designed multiple ligands for cancer therapy Curr. Med. Chem. 18 2011 4722 4737
4. L.K. Gediya, and V.C.O. Njar Promise and challenges in drug discovery and development of hybrid anticancer drugs Expert Opin. Drug Discovery 4 2009 1099 1111
5. R.G. Pertwee Emerging strategies for exploiting cannabinoid receptor agonists as medicines Br. J. Pharmacol. 156 2009 397 411
6. G. Velasco, C. Sanchez, and M. Guzman Towards the use of cannabinoids as antitumour agents Nat. Rev. Cancer 12 2012 436 444
7. M. Guzman Cannabinoids: potential anticancer agents Nat. Rev. Cancer 3 2003 745 755 (Pubitemid 37328813)
8. S. Sarfaraz, V.M. Adhami, D.N. Syed, F. Afaq, and H. Mukhtar Cannabinoids for cancer treatment: progress and promise Cancer Res. 68 2008 339 342 (Pubitemid 351380057)
9. D.H.P. de la Ossa, M. Lorente, M.E. Gil-Alegre, S. Torres, E. Garcia-Taboada, M.D. Aberturas, J. Molpeceres, G. Velasco, and A.I. Torres-Suarez Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme PLoS One 8 2013 e54795
10. C. Grimaldi, and A. Capasso The endocannabinoid system in the cancer therapy: an overview Curr. Med. Chem. 18 2011 1575 1583
11. C.J. Fowler, S.B. Gustafsson, S.C. Chung, E. Persson, S.O.P. Jacobsson, and A. Bergh Targeting the endocannabinoid system for the treatment of cancer - a practical view Curr. Top. Med. Chem. 10 2010 814 827
12. C. Manera, G. Saccomanni, A.M. Malfitano, S. Bertini, F. Castelli, C. Laezza, A. Ligresti, V. Lucchesi, T. Tuccinardi, F. Rizzolio, M. Bifulco, V. Di Marzo, A. Giordano, M. Macchia, and A. Martinelli Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one scaffold Eur. J. Med. Chem. 52 2012 284 294
13. A.M. Malfitano, E. Ciaglia, G. Gangemi, P. Gazzerro, C. Laezza, and M. Bifulco Update on the endocannabinoid system as an anticancer target Expert Opin. Ther. Tar. 15 2011 297 308
14. I. Diaz-Laviada The endocannabinoid system in prostate cancer Nat. Rev. Urol. 8 2011 553 561
15. K. Nithipatikom, M.A. Isbell, M.P. Endsley, J.E. Woodliff, and W.B. Campbell Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells Prostaglandins Other Lipid Mediat. 94 2011 34 43
16. I. Brown, M.G. Cascio, K.W.J. Wahle, R. Smoum, R. Mechoulam, R.A. Ross, R.G. Pertwee, and S.D. Heys Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines Carcinogenesis 31 2010 1584 1591
17. C. Asche Antitumour quinones Mini Rev. Med. Chem. 5 2005 449 467 (Pubitemid 40601636)
18. N.M. Kogan, R. Rabinowitz, P. Levi, D. Gibson, P. Sandor, M. Schlesinger, and R. Mechoulam Synthesis and antitumor activity of quinonoid derivatives of cannabinoids J. Med. Chem. 47 2004 3800 3806 (Pubitemid 38900345)
19. N.M. Kogan, M. Schlesinger, M. Peters, G. Marincheva, R. Beeri, and R.A. Mechoulam Cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study J. Pharmacol. Exp. Ther. 322 2007 646 653 (Pubitemid 47105783)
20. J. Cumella, L. Hernandez-Folgado, R. Giron, E. Sanchez, P. Morales, D.P. Hurst, M. Gomez-Canas, M. Gomez-Ruiz, D.C. Pinto, P. Goya, P.H. Reggio, M.I. Martin, J. Fernandez-Ruiz, A.M. Silva, and N. Jagerovic Chromenopyrazoles: non-psychoactive and selective CB(1) cannabinoid agonists with peripheral antinociceptive properties ChemMedChem 7 2012 452 463
21. S. Akai, and Y. Kita Recent progress in the synthesis of p-quinones and p-dihydro-quinones through oxidation of phenol derivative. A review Org. Prep. Proced. Int. 30 1998 603 629 (Pubitemid 128385889)
22. R. Barret, and M. Daudon Oxidation of phenols to quinones by bis(trifluoroacetoxy)iodobenzene Tetrahedron Lett. 31 1990 4871 4872 (Pubitemid 20251231)
23. S. Malagarie-Cazenave, N. Olea-Herrero, D. Vara, and I. Diaz-Laviada Capsaicin, a component of red peppers, induces expression of androgen receptor via PI3K and MAPK pathways in prostate LNCaP cells FEBS Lett. 583 2009 141 147
24. S. Sarfaraz, F. Afaq, V.M. Adhami, and H. Mukhtar Cannabinoid receptor as a novel target for the treatment of prostate cancer Cancer Res. 65 2005 1635 1641 (Pubitemid 40478586)
25. O.M. Darwish, and G.V. Raj Management of biochemical recurrence after primary localized therapy for prostate cancer Front. Oncol. 2 2012 48
26. M. Grossmann, and J.D. Zajac Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Clin. Endocrinol. 74 2011 289 293
27. M.C. Kim, H.C. Kwon, S.N. Kim, H.S. Kim, and B.H. Um Plastoquinones from Sargassum yezoense; chemical structures and effects on the activation of peroxisome proliferator-activated receptor gamma Chem. Pharm. Bull. 59 2011 834 838
28. J. Xue, W. Ding, and Y. Liu Anti-diabetic effects of emodin involved in the activation of PPAR gamma on high-fat diet-fed and low dose of streptozotocin-induced diabetic mice Fitoterapia 81 2010 173 177
29. C.C. Woo, S.Y. Loo, V. Gee, C.W. Yap, G. Sethi, A.P. Kumar, and K.H. Tan Anticancer activity of thymoquinone in breast cancer cells: possible involvement of PPAR-gamma pathway Biochem. Pharmacol. 82 2011 464 475
30. C.C. Yu, P.J. Wu, J.L. Hsu, Y.F. Ho, L.C. Hsu, Y.J. Chang, H.S. Chang, I.S. Chen, and J.H. Guh Ardisianone, a natural benzoquinone, efficiently induces apoptosis in human hormone-refractory prostate cancers through mitochondrial damage stress and survivin downregulation Prostate 73 2013 133 145
31. C.C. Lee, K.F. Huang, P.Y. Lin, F.C. Huang, C.L. Chen, T.C. Chen, J.H. Guh, J.J. Lin, and H.S. Huang Synthesis, antiproliferative activities and telomerase inhibition evaluation of novel asymmetrical 1,2-disubstituted amidoanthraquinone derivatives Eur. J. Med. Chem. 47 2012 323 336
32. G.Z. Jin, H.S. Jin, and L.L. Jin Synthesis and antiproliferative activity of 1,4-bis(dimethylamino)-9,10-anthraquinone derivatives against P388 mouse leukemic tumor cells Arch. Pharm. Res. 34 2011 1071 1076
33. Y. Kumagai, Y. Shinkai, T. Miura, A.K. Cho, The chemical biology of naphthoquinones and its environmental implications, Annu. Rev. Pharmacol. 52 (2012) 221-247.